Stellar Biotechnologies focuses on stakeholder-responsive principles of corporate governance. We believe these ideas are keys to the success of our company and the trust of our stockholders, employees, customers, suppliers and co-research and development partners. Please report complaints and concerns about our company to any of our members of the Board of Directors.

Please make requests for the company's Articles of Incorporation, By-Laws or Audit Committee documents through the web-site "Contact" page. Such requests will be responded to with the documentation via email.

Stellar Biotechnologies, Inc. (all $ amounts in CDN$)

Symbol:	(KLH on TSX-V; SBOTF on OTC)
Public Filings on www.Sedar.com
CUSIP #:	85855A104
ISIN #:	CA85855A1049
Transfer Agent:
Computershare Trust Company of Canada Vancouver, BC, CANADA
Fiscal Year End:	August 31

 

Canadian Regulatory Address: 1868 King George Highway South Surrey, BC  V4A 5A1 CANADA Tel:  604-306-8854 Fax:  604-535-4454

U.S. Corporate Address: Stellar Biotechnologies, Inc. 332 E. Scott Street Port Hueneme, CA 93041 USA Phone: (805) 488-2147 Fax: (805) 488-1278 www.stellarbiotechnologies.com

Share Structure:

Shares Outstanding:

42,446,181 (as of 09/28/11)

Options Outstanding as of 7/20/10:

75,000 @ $0.25

2,465,000 @ $0.28

Warrants Outstanding as of 7/20/10:

212,000 @ $0.10

1,208,165 @ $0.28

5,751,366 @ $0.40

Performance Shares to certain key employees and advisors subject to certain milestones being met: 6,666,667
 

Banking:

Canada: Royal Bank of Canada

USA: Wells Fargo Bank

Auditor:

D & H Group LLP
Vancouver, BC, CANADA

Corporate & Securities Attorneys:

McMillan LLP
Vancouver, BC, CANADA

Stradling, Yocca, Carlson & Rauth
Santa Barbara, CA, USA

Investor Contact:
dbrookstein@StellarBiotech.com